Sequencing and Preserving Options After Progression

Dr. Gumbleton closes the case by considering how the first-line choice shapes subsequent therapy. Most patients with metastatic disease will eventually progress, making it important to think ahead about what comes next.

He highlights keeping chemotherapy in reserve as a meaningful benefit of a chemotherapy-free first-line choice. For patients who progress rapidly, a relatively uncommon but real scenario, having platinum-based chemotherapy available for the next line, including the option to administer it inpatient in urgent situations, is a practical advantage of starting with amivantamab plus lazertinib rather than osimertinib plus chemotherapy. For patients who started on a chemotherapy-containing first-line regimen, many standard second-line options are expensive and not typically given inpatient, limiting flexibility. Dr. Gumbleton also flags that additional second-line options may become available in the near term, and preserving chemotherapy for a later line may be valuable in that evolving context.

Ultimately, he frames the front-line decision as one of shared decision-making: the evidence does not identify a clearly superior combination regimen, a head-to-head trial is unlikely to emerge, and the most appropriate approach is to present the trade-offs—survival data, CNS protection, adverse effect profiles, administration schedule, and sequencing implications—and support the patient in choosing what aligns with her priorities.

Dr. Gumbleton's summary: this case highlights how a TP53 co-mutation at diagnosis meaningfully informs first-line treatment selection in EGFR-driven NSCLC, and how clinicians weigh the survival differences between MARIPOSA and FLAURA2, the benefit of combination regimens in high-risk populations, the distinct safety profiles, and the proactive strategies that help patients tolerate these therapies.

Thank you for watching this Case-Based Peer Perspectives on first-line treatment selection in TP53 co-mutated EGFR-positive metastatic NSCLC. Please subscribe to our e-newsletter for information on upcoming video series.